首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1791篇
  免费   1篇
化学工业   14篇
金属工艺   3篇
建筑科学   4篇
矿业工程   1篇
能源动力   2篇
轻工业   7篇
无线电   1篇
一般工业技术   2篇
冶金工业   1750篇
自动化技术   8篇
  2022年   1篇
  2021年   1篇
  2017年   1篇
  2016年   1篇
  2013年   2篇
  2011年   3篇
  2010年   2篇
  2009年   3篇
  2008年   1篇
  2007年   2篇
  2006年   2篇
  2005年   4篇
  2004年   3篇
  2003年   9篇
  2002年   2篇
  2001年   2篇
  2000年   2篇
  1999年   71篇
  1998年   593篇
  1997年   292篇
  1996年   200篇
  1995年   119篇
  1994年   106篇
  1993年   104篇
  1992年   4篇
  1991年   17篇
  1990年   26篇
  1989年   11篇
  1988年   20篇
  1987年   8篇
  1986年   13篇
  1985年   7篇
  1984年   1篇
  1983年   2篇
  1982年   9篇
  1981年   10篇
  1980年   8篇
  1979年   1篇
  1978年   5篇
  1977年   40篇
  1976年   80篇
  1975年   3篇
  1959年   1篇
排序方式: 共有1792条查询结果,搜索用时 15 毫秒
31.
32.
33.
In this paper, a comparison between two methods: the Adomian decomposition method and the variational iteration method, used for solving the moving boundary problem, is presented. Both of the methods consist in constructing the appropriate iterative or recurrence formulas, on the basis of the equation considered and additional conditions, enabling one to determine the successive elements of a series or sequence approximating the function sought. The precision and speed of convergence of the procedures compared are verified with an example.  相似文献   
34.
The article concludes a series of results on cut-rule axiomatizabilityof the Lambek calculus. It is proved that the non-associativeproduct-free Lambek calculus with the empty string (NL0) isnot finitely axiomatizable if the only rule of inference admittedis Lambek's cut rule. The proof makes use of the (infinitely)cut-rule axiomatized calculus NC designed by the author exactlyfor that purpose.  相似文献   
35.
OBJECTIVE: To describe assisted reproductive technology (ART) and use of medications during these procedures. DATA SOURCES: Recent clinical literature. STUDY SELECTION: Not applicable. DATA EXTRACTION: Not applicable. DATA SYNTHESIS: ARTs are procedures used in treatment of infertility that involve removal of oocytes and their manipulation outside the woman's uterus. The simplest form of ART, in vitro fertilization, involves aspirating eggs from the ovaries, fertilizing them outside the body, and transferring the embryos into the uterus at the four- to eight-cell stage. Experimental regimens for in vitro fertilization include use of various medications (gonadotropin-releasing hormone agonists, human menotropins, follicle-stimulating hormone, growth hormone) at varying points in the menstrual cycle and after introduction of the embryo into the uterus. Human chorionic gonadotropin has been used to increase implantation of embryos during the woman's luteal phase. Gamete intrafallopian transfer (GIFT) involves transfer of oocytes and sperm into the fallopian tubes, where fertilization takes place. This technique has the advantage of causing the zygote to enter the uterus at the time it would during natural conception. Zygote intrafallopian transfer is similar to GIFT, except that fertilization occurs in vitro, with embryos placed in the fallopian tubes at the two-cell stage. Various micromanipulation techniques and innovative sperm aspiration procedures are currently under development. CONCLUSION: Many advancements have been made in ART, and pharmacists who understand these procedures can serve patients by providing medication information in an empathetic and supportive manner.  相似文献   
36.
37.
Combination therapy with intravesical bacillus Calmette-Guérin (BCG) plus IFN-alpha for superficial bladder cancer has been demonstrated to be more effective than either single agent alone in animal studies and of suggested greater efficacy in clinical studies. However, the mechanism by which IFN-alpha enhances BCG-mediated antitumor activity is poorly understood. Using PBMCs from bladder cancer patients, IFN-alpha was found to substantially enhance the efficacy of BCG to induce IFN-gamma production. Among 34 patients tested, 80% showed >4-fold increase. This effect of IFN-alpha was observed in both initial and memory responses to BCG. In addition, IFN-alpha up-regulated BCG-induced IL-12 and TNF-alpha and down-regulated BCG-induced IL-10. Neutralizing endogenous IL-10 or adding exogenous IL-12 provided further synergy for IFN-gamma production. In clinical practice, intravesical IFN-alpha 2B (50 million units (MU)/dose) was observed to accelerate urinary IFN-gamma production to low-dose BCG (one-tenth or one-third of a full dose) in patients treated with combination therapy compared with BCG alone. These results suggest that IFN-alpha is a potent BCG enhancer that polarizes the BCG-induced immune response toward the cellular immune pathway by promoting Th1 cytokine expression and reducing Th2 cytokine expression. This study provides an immunological basis for future rational use of IFN-alpha in conjunction with intravesical BCG for bladder cancer immunotherapy.  相似文献   
38.
39.
40.
We have developed a new detection method for measuring distributions of energy depositions from particles characterized by low linear energy transfers (LETs). In particular, we have developed a detection system to measure energy depositions produced by electrons and photons on nanometer scales. The detector is based upon the operational principles of the superheated drop detector (SDD). SDDs consist of tiny droplets of superheated liquid suspended within a gel-like emulsion. The SDDs in this study are fabricated using Freon-115 and a glycerol-based gel as the superheated liquid and host medium. This SDD configuration is operated as a threshold temperature-dependent detector for measuring nanoscopic distributions of energy depositions from low-LET particles. Measured results are compared to the calculated distributions of energy depositions along an electron track. A new electron track code, ESLOW3.1, is used to perform the computational study. Measurements show good agreement with computational results in the energy deposition range of 40-200 eV.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号